Helicobacter pylori-negative gastritis: Prevalence and risk factors

American Journal of Gastroenterology

Volumn 108, Issue 1, 2013, Pages 65-71

  Nordenstedt, Helena ^a,b   Graham, David Y ^b,c   Kramer, Jennifer R ^a,b   Rugge, Massimo ^b,d   Verstovsek, Gordana ^e   Fitzgerald, Stephanie ^a   Alsarraj, Abeer ^a   Shaib, Yasser ^b,c   Velez, Maria E ^b,c   Abraham, Neena ^a,b,c   Anand, Bhupinderjit ^b,c   Cole, Rhonda ^b,c   El Serag, Hashem B ^a,b,c  

^a VA HSRandD Houston Center of Excellence   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Department of Medicine ^*  (United States)

^d UNIVERSITY OF PADOVA   (Italy)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

AGED; ARTICLE; BACTERIUM CULTURE; DRINKING BEHAVIOR; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTRITIS; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; SMOKING; STOMACH ANTRUM; STOMACH BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CROSS-SECTIONAL STUDIES; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; GASTRIC MUCOSA; GASTRITIS; HEALTH SURVEYS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; TEXAS;

EID: 84872007015     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.372     Document Type: Article

References (11)

1. Di Napoli A, Petrino R, Boero M et al. Quantitative assessment of histological changes in chronic gastritis aft er eradication of Helicobacter pylori. J Clin Pathol 1992; 45: 796-8.
2. Sung JJ, Lin SR, Ching JY et al. Atrophy and intestinal metaplasia one year aft er cure of H. pylori infection: a prospective, randomized study. Gastroenterol 2000; 119: 7-14.
3. Haber MM, Hunt B, Freston JW et al. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. Aliment Pharmacol Ther 2010; 32: 83-96.
4. Peura DA, Haber MM, Hunt B et al. Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. J Clin Gastroenterol 2010; 44: 180-5.
5. Merchant SH, VanderJagt T, Lathrop S et al. Sporadic duodenal bulb gastrin-cell tumors: association with Helicobacter pylori gastritis and longterm use of proton pump inhibitors. Am J Surg Pathol 2006; 30: 1581-7.
6. Dixon MF, Genta RM, Yardley JH et al. Classification and grading of gastritis. Th e updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
7. van Der Ende A, van Der Hulst RW, Roorda P et al. Evaluation of three commercial serological tests with different methodologies to assess Helicobacter pylori infection. J Clin Microbiol 1999; 37: 4150-2.
8. Rugge M, de Boni M, Pennelli G et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31: 1104-11.
9. Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40: 650-8.
10. Cutler AF, Prasad VM, Santogade P. Four-year trends in Helicobacter pylori IgG serology following successful eradication. Am J Med 1998; 105: 18-20.
11. Zavros Y, Rieder G, Ferguson A et al. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterol 2002; 122: 119-33.